These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 34734491)

  • 1. Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma.
    Wang H; Wang X; Xu L; Cao H; Zhang J
    Cancer Med; 2021 Dec; 10(24):9058-9077. PubMed ID: 34734491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
    Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
    Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis.
    Zhang MY; Liu XX; Li H; Li R; Liu X; Qu YQ
    Int J Med Sci; 2018; 15(14):1676-1685. PubMed ID: 30588191
    [No Abstract]   [Full Text] [Related]  

  • 4. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
    Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
    PeerJ; 2023; 11():e16166. PubMed ID: 37790630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification Six Metabolic Genes as Potential Biomarkers for Lung Adenocarcinoma.
    Zhang S; Lu Y; Liu Z; Li X; Wang Z; Cai Z
    J Comput Biol; 2020 Oct; 27(10):1532-1543. PubMed ID: 32298601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Expression of
    Deng H; Huang Y; Wang L; Chen M
    Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [miR-218-5p Targeting TPX2 Regulates p53 Pathway and Inhibits Malignant Progression of Lung Adenocarcinoma].
    Xu J
    Zhongguo Fei Ai Za Zhi; 2023 Oct; 26(10):721-731. PubMed ID: 37989335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma.
    Li S; Li H; Cao Y; Geng H; Ren F; Li K; Dai C; Li N
    Medicine (Baltimore); 2021 Aug; 100(32):e26474. PubMed ID: 34397869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid metabolism-related gene prognostic index (LMRGPI) reveals distinct prognosis and treatment patterns for patients with early-stage pulmonary adenocarcinoma.
    Jiang A; Chen X; Zheng H; Liu N; Ding Q; Li Y; Fan C; Fu X; Liang X; Tian T; Ruan Z; Yao Y
    Int J Med Sci; 2022; 19(4):711-728. PubMed ID: 35582412
    [No Abstract]   [Full Text] [Related]  

  • 14. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
    Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
    Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of four metabolic subtypes and key prognostic markers in lung adenocarcinoma based on glycolytic and glutaminolytic pathways.
    Zhang J; Wang X; Song C; Li Q
    BMC Cancer; 2023 Feb; 23(1):152. PubMed ID: 36782138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Prognostic Biomarkers of Lung Adenocarcinoma Based on Bioinformatic Analysis.
    Hou J; Yao C
    Biomed Res Int; 2021; 2021():8859996. PubMed ID: 33511215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of KIF4A and its effect on the progression of lung adenocarcinoma based on the bioinformatics analysis.
    Song Y; Tang W; Li H
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33398330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma.
    Jin J; Liu C; Yu S; Cai L; Sitrakiniaina A; Gu R; Li W; Wu F; Xue X
    Aging (Albany NY); 2021 Jun; 13(12):16144-16164. PubMed ID: 34115610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight-gene signature predicts recurrence in lung adenocarcinoma.
    Zhang Y; Fan Q; Guo Y; Zhu K
    Cancer Biomark; 2020; 28(4):447-457. PubMed ID: 32508318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.